13F Holdings
中文EN

GYRE GYRE THERAPEUTICS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1124105 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY8.4%
TTM net income YoY-801.1%
TTM EPS YoY-2,500.0%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin94.1%
Operating margin-20.6%
Net margin-30.1%
FCF margin-20.3%
EBITDA margin-18.8%

Returns

ROE-34.9%
ROA-20.3%
ROIC (approx.)-31.0%
Asset turnover0.68x

Leverage & solvency

Liabilities / assets17.5%
Debt / equity0.00x
Current ratio4.32x
Interest coverage—

Cash quality & payout

Operating cash flow / net income0.63x
Accruals ratio-7.5%
Payout ratio—
Capex / revenue1.3%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$116.59M$105.76M$113.45M$102.29M$7.34M
Cost of revenue$5.42M$3.88M$4.64M$4.79M—
Gross profit$111.17M$101.87M$108.81M$97.50M—
R&D expense$13.70M$12.02M$13.78M$16.69M$68.89M
SG&A expense$20.80M$16.11M$14.66M$17.37M$18.96M
Operating income$11.49M$16.16M-$67.23M$9.20M-$87.89M
Pretax income$14.44M$23.22M-$76.97M$9.41M-$87.93M
Income tax$4.56M$5.32M$8.52M$5.10M—
Net income$9.88M$17.90M-$85.48M$4.31M-$87.93M
EBITDA$13.97M$17.71M-$66.16M$10.29M-$87.60M
EPS (basic)0.060.14-1.410.04-2.87
EPS (diluted)0.020.05-1.410.03-2.87
Dividends declared per share———0.24—
Weighted avg. shares (diluted)103.18M102.29M65.83M75.69M30.64M
Banking
Net interest income$1.75M$1.55M$1.04M$726,000—
Balance sheet
Cash & equivalents$49.19M$11.81M$33.51M$25.18M$44.35M
Short-term investments$15.36M$14.86M—$0$2.50M
Receivables$31.08M$19.59M$15.16M—$1.82M
Inventory$10.17M$6.34M$4.28M$6.12M—
Current assets$149.36M$64.79M$57.22M$49.65M$51.48M
PP&E, net$27.55M$23.88M$23.29M$17.71M$970,000
Intangibles$4.73M$273,000$273,000$297,000—
Total assets$219.76M$125.41M$116.54M$84.75M$55.66M
Current liabilities$23.78M$19.52M$20.05M$12.24M$14.16M
Total liabilities$31.40M$27.00M$38.06M$12.54M$14.57M
Shareholders' equity$62.50M$63.32M-$15.83M$42.52M$41.09M
Shares outstanding91.31M86.31M76.60M63.59M31.41M
Cash flow statement
Operating cash flow$1.01M-$3.64M$25.89M$10.68M-$83.75M
Capital expenditure$1.19M$2.31M$8.52M$4.99M$839,000
Free cash flow-$180,000-$5.96M$17.38M$5.69M-$84.59M
Investing cash flow-$474,000-$19.88M-$19.76M-$13.81M$48.19M
Financing cash flow$24.38M$2.10M$2.50M-$45.01M$49.55M
Depreciation & amortization$2.48M$1.55M$1.07M$1.09M$290,000
Stock-based compensation$7.16M$831,000$7.28M$13.37M$3.40M
Dividends paid———$45.03M—

Free plan shows the latest 5 periods; Pro shows all 17 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.